Skip to content

M.l. Williams

12 papers in the library · 232 citations · publishing 2017-2026

Papers

Sort Most recent Most cited

The Australian Ayahuasca Dietero Networks: Culture, Community, and Practices

Contemporary Drug Problems August 11, 2026 Alana Roy, M.l. Williams, Kimberley Day et al.

Alternative healthcare practices using psychedelic “plant medicines,” such as ayahuasca, challenge current prohibition and mainstream healthcare frameworks. Despite the criminalization of ayahuasca's active component, N,N-dimethyltryptamine (DMT), Australian ayahuasca dietero networks have developed sophisticated healthcare systems with systematic assessment processes, safety mechanisms, and...

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

Therapeutic Advances in Psychopharmacology September 1, 2025 Sally Meikle, Olivia Carter, Paul Liknaitzky et al. 2 citations

Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research. Objectives: This study aimed to evaluate the feasibility, safety and effectiveness of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD), investigate predictors of...

Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial

General Hospital Psychiatry August 12, 2025 Margaret Ross, Ravi Iyer, M.l. Williams et al. 13 citations

Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illness.

DOI: 10.1016/j.genhosppsych.2025.08.001 (opens in new tab) Psilocybin Anxiety Randomized controlled trial Psychotherapist +3

229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL

The International Journal of Neuropsychopharmacology August 1, 2025 Susan Meikle, Olivia Carter, Paul Liknaitzky et al.

Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left with residual symptoms such as impairments in cognition and social functioning. Emerging psychedelic therapies show promise for treating depression but require further research. Aims & Objectives This pilot study aimed to evaluate the feasibility,...

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol

October 7, 2024 Jennifer Pincombe, M.l. Williams, Sean Carruthers et al. 1 citation preprint

IntroductionThere has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may be an effective novel intervention for several mental health disorders. Researchers are increasingly incorporating qualitative analysis into their studies in recognition of the rich, contextual information this provides. This scoping review aims to...

DOI: 10.31234/osf.io/ga9p2 (opens in new tab) Psilocybin Psychotherapist Mental health Protocol science +5

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead

Frontiers in Psychiatry November 4, 2021 M.l. Williams, Diana Korevaar, Renee Harvey et al. 23 citations

Research exploring the potential of psychedelic-assisted therapies to treat a range of mental illnesses is flourishing, after the problematic sociopolitical history of psychedelics led to the shutdown of clinical research for almost 40 years. Encouraged by positive results, clinicians and patients are now hopeful that further interruptions to research will be avoided, so that the early promise...

DOI: 10.3389/fpsyt.2021.737738 (opens in new tab) Flourishing Context archaeology Multidisciplinary approach Clinical trial +2

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

Australian & New Zealand Journal of Psychiatry March 21, 2021 Daniel Perkins, Jerome Sarris, Susan L. Rossell et al. 53 citations

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on...

DOI: 10.1177/0004867421998785 (opens in new tab) Psilocybin Mental health Psychotherapist Hallucinogen

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models

Frontiers in Neuroscience February 4, 2020 Claire J. Foldi, Paul Liknaitzky, M.l. Williams et al. 52 citations

Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the...

Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications

Journal of Music Therapy 2020 Clare O’callaghan, Daniel John Hubik, Justin Dwyer et al. 50 citations

Abstract Bonny Method of Guided Imagery and Music emerged following discontinuation of psychedelic therapy research in the early 1970s, but psychedelic therapy research has since revived. Music remains a vital component. This study examined participants’ experiences of music in psychedelic therapy research. A rapid review of qualitative and quantitative journal articles in four major databases...

Psilocybin-assisted therapy for depression: How do we advance the field?

Australian & New Zealand Journal of Psychiatry November 22, 2019 Sally Meikle, Paul Liknaitzky, Susan L. Rossell et al. 19 citations

In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment,...

DOI: 10.1177/0004867419888575 (opens in new tab) Psilocybin Hallucinogen Psychotherapist Depression economics +4

Should addiction researchers be interested in psychedelic science?

Drug and Alcohol Review April 10, 2017 Stephen Bright, M.l. Williams, David Caldicott 5 citations

As recently noted by Strauss, Bright and Williams 1, while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade 2, there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function 3 and reduced...